Interleukin-6 as an enhancer of anti-angiogenic therapy for ovarian clear cell carcinoma

Ovarian clear cell carcinoma (OCCC) is a subtype of epithelial ovarian cancer (EOC) that is associated with elevated interleukin-6 (IL-6) expression, resistance to chemotherapy, and increased mortality. Although bevacizumab (Bev) is a widely used anti-angiogenic agent for EOC, the efficacy of Bev an...

Descripción completa

Detalles Bibliográficos
Autores principales: Seki, Toshiyuki, Yanaihara, Nozomu, Shapiro, Jason Solomon, Saito, Misato, Tabata, Junya, Yokomizo, Ryo, Noguchi, Daito, Kuroda, Takafumi, Kawabata, Ayako, Suzuki, Jiro, Takahashi, Kazuaki, Matsuzawa, Haruka, Miyake, Misayo, Takenaka, Masataka, Iida, Yasushi, Yanagida, Satoshi, Okamoto, Aikou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8032732/
https://www.ncbi.nlm.nih.gov/pubmed/33833265
http://dx.doi.org/10.1038/s41598-021-86913-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8032732/
https://www.ncbi.nlm.nih.gov/pubmed/33833265
http://dx.doi.org/10.1038/s41598-021-86913-9

Ejemplares similares